AstraZeneca says 4th-Q earns triple on cancer drugs sales
AstraZeneca, co-developer of one of the first COVID-19 vaccines to be authorized for widespread use, says fourth-quarter earnings more than tripled amid strong sales of cancer drugs
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.AstraZeneca co-developer of one of the first COVID-19 vaccines to be authorized for widespread use, says fourth-quarter earnings more than tripled amid strong sales of its cancer drugs.
The Anglo-Swedish company said Thursday that net income rose to $1.01 billion from $313 million in the same quarter a year earlier.
Drug sales increased 11% to $7.41 billion, driven by a 24% increase in cancer treatments.
The company posted $2 million of revenue from its COVID-19 vaccine, which it has pledged to supply on a non-profit basis during the pandemic, and said it would begin reporting sales of the vaccine separately beginning in the next quarter.
Subscribe to Independent Premium to bookmark this article
Want to bookmark your favourite articles and stories to read or reference later? Start your Independent Premium subscription today.